In this paper, we propose an approach to support the diagnosis of urinary tract diseases, with a focus on bladder cancer, using SHAP (SHapley Additive exPlanations)-based feature selection to enhance the transparency and effectiveness of predictive models. Six binary classification scenarios were developed to distinguish bladder cancer from other urological and oncological conditions. The algorithms XGBoost, LightGBM, and CatBoost were employed, with hyperparameter optimization performed using Optuna and class balancing with the SMOTE technique. The selection of predictive variables was guided by importance values through SHAP-based feature selection while maintaining or even improving performance metrics such as balanced accuracy, precision, and specificity. The use of explainability techniques (SHAP) for feature selection proved to be an effective approach. The proposed methodology may contribute to the development of more transparent, reliable, and efficient clinical decision support systems, optimizing screening and early diagnosis of urinary tract diseases.

Clinical cystoscopy, the current standard for bladder cancer diagnosis, suffers from significant reliance on physician expertise, leading to variability and subjectivity in diagnostic outcomes. There is an urgent need for objective, accurate, and efficient computational approaches to improve bladder cancer diagnostics. Leveraging recent advancements in deep learning, this study proposes an integrated multi-task deep learning framework specifically designed for bladder cancer diagnosis from cystoscopic images. Our framework includes a robust classification model using EfficientNet-B0 enhanced with Convolutional Block Attention Module (CBAM), an advanced segmentation model based on ResNet34-UNet++ architecture with self-attention mechanisms and attention gating, and molecular subtyping using ConvNeXt-Tiny to classify molecular markers such as HER-2 and Ki-67. Additionally, we introduce a Gradio-based online diagnostic platform integrating all developed models, providing intuitive features including multi-format image uploads, bilingual interfaces, and dynamic threshold adjustments. Extensive experimentation demonstrates the effectiveness of our methods, achieving outstanding accuracy (93.28%), F1-score (82.05%), and AUC (96.41%) for classification tasks, and exceptional segmentation performance indicated by a Dice coefficient of 0.9091. The online platform significantly improved the accuracy, efficiency, and accessibility of clinical bladder cancer diagnostics, enabling practical and user-friendly deployment. The code is publicly available. Our multi-task framework and integrated online tool collectively advance the field of intelligent bladder cancer diagnosis by improving clinical reliability, supporting early tumor detection, and enabling real-time diagnostic feedback. These contributions mark a significant step toward AI-assisted decision-making in urology.

After Hall of Fame athlete Deion Sanders' announcement that he battled bladder cancer, doctors are sharing warning signs to monitor. Sanders, who is currently head football coach at the University of Colorado Boulder, spoke about his medical struggles during a Monday press conference held at Folsom Field in Boulder. The former NFL and MLB star, 57, appeared alongside his care team and representatives from University of Colorado Health (UC Health) and University of Colorado Anschutz Medical Campus (CU Anschutz). Sanders was diagnosed with "very high-risk, non-muscle invasive bladder cancer," but is now cancer-free, according to a statement from his oncologist. It was very high-grade and invading through the bladder wall," said Dr. Janet Kukreja, urological oncology director at CU Anshutz. "I am pleased to report that the results from the surgery are that he is cured from the cancer." Head coach Deion Sanders of the University of Colorado speaks about his journey beating bladder cancer during a press conference in the Touchdown Club at Folsom Field in Boulder, Colorado, on July 28, 2025. The oncologist noted that Sanders' type of cancer has a very high rate of recurrence and progression. Treating the disease within the bladder would require a long series of treatments over a three-year period, and there would still be a 50% chance of the cancer coming back. The cancer could also have spread to the muscle, the doctor said, which happens in about half of cases. "Only about 10% of people live five years, even with our current medical treatment, if it metastasizes," she said. Together with his care team, Sanders made the decision to have a bladder removal, in which surgeons performed a "full robot-assisted laparoscopic bladder removal" and created a new bladder. "It is a new way of life.

The increasing availability of large-scale omics data calls for robust analytical frameworks capable of handling complex gene expression datasets while offering interpretable results. Recent advances in artificial intelligence have enabled the identification of aberrant molecular patterns distinguishing disease states from healthy controls. Coupled with improvements in model interpretability, these tools now support the identification of genes potentially driving disease phenotypes. However, current approaches to gene anomaly detection often remain limited to single datasets and lack accessible graphical interfaces. Here, we introduce E-ABIN, a general-purpose, explainable framework for Anomaly detection in Biological Networks. E-ABIN combines classical machine learning and graph-based deep learning techniques within a unified, user-friendly platform, enabling the detection and interpretation of anomalies from gene expression or methylation-derived networks. By integrating algorithms such as Support Vector Machines, Random Forests, Graph Autoencoders (GAEs), and Graph Adversarial Attributed Networks (GAANs), E-ABIN ensures a high predictive accuracy while maintaining interpretability. We demonstrate the utility of E-ABIN through case studies of bladder cancer and coeliac disease, where it effectively uncovers biologically relevant anomalies and offers insights into disease mechanisms.

Non-muscle-invasive bladder cancer (NMIBC) is a relentless challenge in oncology, with recurrence rates soaring as high as 70-80%. Each recurrence triggers a cascade of invasive procedures, lifelong surveillance, and escalating healthcare costs - affecting 460,000 individuals worldwide. However, existing clinical prediction tools remain fundamentally flawed, often overestimating recurrence risk and failing to provide personalized insights for patient management. In this work, we propose an interpretable deep learning framework that integrates vector embeddings and attention mechanisms to improve NMIBC recurrence prediction performance. We incorporate vector embeddings for categorical variables such as smoking status and intravesical treatments, allowing the model to capture complex relationships between patient attributes and recurrence risk. These embeddings provide a richer representation of the data, enabling improved feature interactions and enhancing prediction performance. Our approach not only enhances performance but also provides clinicians with patient-specific insights by highlighting the most influential features contributing to recurrence risk for each patient. Our model achieves accuracy of 70% with tabular data, outperforming conventional statistical methods while providing clinician-friendly patient-level explanations through feature attention. Unlike previous studies, our approach identifies new important factors influencing recurrence, such as surgical duration and hospital stay, which had not been considered in existing NMIBC prediction models.

In the current field of clinical medicine, traditional methods for analyzing recurrent events have limitations when dealing with complex time-dependent data. This study combines Long Short-Term Memory networks (LSTM) with the Cox model to enhance the model's performance in analyzing recurrent events with dynamic temporal information. Compared to classical models, the LSTM-Cox model significantly improves the accuracy of extracting clinical risk features and exhibits lower Akaike Information Criterion (AIC) values, while maintaining good performance on simulated datasets. In an empirical analysis of bladder cancer recurrence data, the model successfully reduced the mean squared error during the training phase and achieved a Concordance index of up to 0.90 on the test set. Furthermore, the model effectively distinguished between high and low-risk patient groups, and the identified recurrence risk features such as the number of tumor recurrences and maximum size were consistent with other research and clinical trial results. This study not only provides a straightforward and efficient method for analyzing recurrent data and extracting features but also offers a convenient pathway for integrating deep learning techniques into clinical risk prediction systems.

We present a pioneering investigation into the application of deep learning techniques to analyze histopathological images for addressing the substantial challenge of automated prognostic prediction. Prognostic prediction poses a unique challenge as the ground truth labels are inherently weak, and the model must anticipate future events that are not directly observable in the image. To address this challenge, we propose a novel three-part framework comprising of a convolutional network based tissue segmentation algorithm for region of interest delineation, a contrastive learning module for feature extraction, and a nested multiple instance learning classification module. Our study explores the significance of various regions of interest within the histopathological slides and exploits diverse learning scenarios. The pipeline is initially validated on artificially generated data and a simpler diagnostic task. Transitioning to prognostic prediction, tasks become more challenging. Employing bladder cancer as use case, our best models yield an AUC of 0.721 and 0.678 for recurrence and treatment outcome prediction respectively.

Bladder cancer, the leading urinary tract cancer, is responsible for 15 deaths daily in the UK. This cancer predominantly manifests as non-muscle-invasive bladder cancer (NMIBC), characterised by tumours not yet penetrating the muscle layer of the bladder wall. NMIBC is plagued by a very high recurrence rate of 70-80% and hence the costliest treatments. Current tools for predicting recurrence use scoring systems that overestimate risk and have poor accuracy. Inaccurate and delayed prediction of recurrence significantly elevates the likelihood of mortality. Accurate prediction of recurrence is hence vital for cost-effective management and treatment planning. This is where Machine learning (ML) techniques have emerged as a promising approach for predicting NMIBC recurrence by leveraging molecular and clinical data. This review provides a comprehensive analysis of ML approaches for predicting NMIBC recurrence. Our systematic evaluation demonstrates the potential of diverse ML algorithms and markers, including radiomic, clinical, histopathological, genomic, and biochemical data in enhancing recurrence prediction and personalised patient management. We summarise various prediction tasks, data modalities, and ML models used, highlighting their performance, limitations, and future directions of incorporating cost-effectiveness. Challenges related to generalisability and interpretability of artificial intelligent models are discussed, emphasising the need for collaborative efforts and robust datasets.

Nanorobots that move through the bloodstream could reduce cancerous tumors in the bladder by 90 percent. In a potential breakthrough, scientists in Barcelona created tiny 450-nanometer-sized robots that deliver therapeutic directly to the growth. Bladder cancer is the one of the common type of cancer in men and while it has a low mortality rate nearly all tumors return within five years. In a study on mice, researchers showed that the tiny machines could eliminate the need for multiple tumor treatments by reducing the tumor after one try. Current treatments for bladder cancer include surgery and chemotherapy, which can cost more than 65,000.

Cancer is one of the most widespread diseases around the world with millions of new patients each year. Bladder cancer is one of the most prevalent types of cancer affecting all individuals alike with no obvious prototypical patient. The current standard treatment for BC follows a routine weekly Bacillus Calmette-Guerin (BCG) immunotherapy-based therapy protocol which is applied to all patients alike. The clinical outcomes associated with BCG treatment vary significantly among patients due to the biological and clinical complexity of the interaction between the immune system, treatments, and cancer cells. In this study, we take advantage of the patient's socio-demographics to offer a personalized mathematical model that describes the clinical dynamics associated with BCG-based treatment. To this end, we adopt a well-established BCG treatment model and integrate a machine learning component to temporally adjust and reconfigure key parameters within the model thus promoting its personalization. Using real clinical data, we show that our personalized model favorably compares with the original one in predicting the number of cancer cells at the end of the treatment, with 14.8% improvement, on average.